Payment overview · 2025
General Payments
$17,724.10
221 reported records · 22 companies
Healthcare provider profile · identity verified
Michael J Attanasio, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · PHILADELPHIA, PA · NPI 1174593958
Verified facts
What the public records show
CMS Open Payments records show Michael J Attanasio, D.O. received $17,724.10 in general payments during 2025 across 221 reported records.
Amgen Inc. accounted for 55.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Farxiga, Jardiance, Kerendia, Linzess, Mounjaro, Ozempic, Rybelsus, Synthroid, Trelegy Ellipta, Trintellix, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Ubrelvy by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 195 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 195 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Paxlovid by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $9,810.04 | 55.4% | 30 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $5,068.28 | 28.6% | 45 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $609.27 | 3.4% | 17 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $505.40 | 2.9% | 27 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $227.43 | 1.3% | 19 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $224.97 | 1.3% | 14 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $210.60 | 1.2% | 12 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $197.97 | 1.1% | 9 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $179.40 | 1.0% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $169.39 | 1.0% | 10 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $162.02 | 0.9% | 11 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $70.63 | 0.4% | 5 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $52.64 | 0.3% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $51.20 | 0.3% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $36.94 | 0.2% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $33.76 | 0.2% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $33.40 | 0.2% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $20.88 | 0.1% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $17.89 | 0.1% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.25 | 0.1% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.93 | 0.1% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $13.81 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12,900.00 | 7 |
| Food and Beverage | $3,942.54 | 213 |
| Travel and Lodging | $881.56 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $9,767.34 | 28 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $4,801.01 | 21 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $4,778.56 | 20 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $482.35 | 9 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $434.92 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $395.26 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $227.43 | 19 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $224.97 | 14 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $219.01 | 19 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $197.97 | 9 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $179.40 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $177.73 | 15 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $172.85 | 10 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $168.31 | 14 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $165.19 | 8 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $162.02 | 11 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $133.81 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $127.24 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $105.60 | 7 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $70.63 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $67.12 | 5 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $60.02 | 8 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $60.02 | 8 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $52.64 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $51.20 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $42.70 | 2 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $39.99 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $28.73 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $27.00 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $22.06 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $20.88 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.38 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $16.34 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $14.25 | 1 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $13.93 | 1 | 2025 |
Source payment records
|
|||||
| XTAMPZA Normalized: xtampza |
Drug | Collegium Pharmaceutical, Inc. | $13.81 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $11.42 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 195 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 107 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 135 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 58 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 105 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 115 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 80 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 90 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 96 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
90 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
107 | 30 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
58 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
135 | 33 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
195 | 39 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
96 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
135 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
105 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
115 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
80 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
195 | 39 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
24 | 23 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1005 | 282 |
| Atorvastatin Calcium | Atorvastatin Calcium | 649 | 165 |
| Amlodipine Besylate | Amlodipine Besylate | 600 | 162 |
| Omeprazole | Omeprazole | 451 | 111 |
| Oxycodone Hcl | Oxycodone Hcl | 442 | 45 |
| Losartan Potassium | Losartan Potassium | 409 | 110 |
| Levothyroxine Sodium | Levothyroxine Sodium | 400 | 98 |
| Alprazolam | Alprazolam | 382 | 58 |
| Lisinopril | Lisinopril | 353 | 86 |
| Ezetimibe | Ezetimibe | 294 | 90 |
| Metformin Hcl | Metformin Hcl | 293 | 78 |
| Gabapentin | Gabapentin | 287 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 274 | 69 |
| Alendronate Sodium | Alendronate Sodium | 252 | 64 |
| Carvedilol | Carvedilol | 246 | 62 |
| Famotidine | Famotidine | 235 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 230 | 59 |
| Furosemide | Furosemide | 218 | 62 |
| Fluticasone Propionate | Fluticasone Propionate | 215 | 77 |
| Duloxetine Hcl | Duloxetine Hcl | 197 | 42 |
| Eliquis | Apixaban | 195 | 39 |
| Trazodone Hcl | Trazodone Hcl | 192 | 41 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 190 | 24 |
| Lorazepam | Lorazepam | 188 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 184 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 180 | 42 |
| Tramadol Hcl | Tramadol Hcl | 166 | 35 |
| Montelukast Sodium | Montelukast Sodium | 147 | 38 |
| Diazepam | Diazepam | 139 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 139 | 37 |
| Jardiance | Empagliflozin | 135 | 33 |
| Azithromycin | Azithromycin | 132 | 96 |
| Cefuroxime | Cefuroxime Axetil | 132 | 95 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 130 | 35 |
| Sertraline Hcl | Sertraline Hcl | 129 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 125 | 43 |
| Buspirone Hcl | Buspirone Hcl | 120 | 29 |
| Methylprednisolone | Methylprednisolone | 117 | 81 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 116 | 73 |
| Xarelto | Rivaroxaban | 116 | 27 |
| Ozempic | Semaglutide | 115 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 111 | 74 |
| Repatha Sureclick | Evolocumab | 109 | 22 |
| Farxiga | Dapagliflozin Propanediol | 107 | 30 |
| Ibuprofen | Ibuprofen | 106 | 26 |
| Mounjaro | Tirzepatide | 105 | 22 |
| Mirtazapine | Mirtazapine | 103 | 30 |
| Potassium Chloride | Potassium Chloride | 102 | 25 |
| Vascepa | Icosapent Ethyl | 100 | 22 |
| Donepezil Hcl | Donepezil Hcl | 99 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 96 | 16 |
| Morphine Sulfate Er | Morphine Sulfate | 94 | suppressed |
| Synthroid | Levothyroxine Sodium | 90 | 16 |
| Clonazepam | Clonazepam | 89 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 86 | 14 |
| Ramipril | Ramipril | 83 | 25 |
| Simvastatin | Simvastatin | 82 | 24 |
| Rybelsus | Semaglutide | 80 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 77 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 72 | 24 |
| Finasteride | Finasteride | 70 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | 18 |
| Meclizine Hcl | Meclizine Hcl | 69 | 20 |
| Valsartan | Valsartan | 67 | 23 |
| Allopurinol | Allopurinol | 64 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 62 | 14 |
| Pregabalin | Pregabalin | 61 | 12 |
| Kerendia | Finerenone | 58 | 14 |
| Icosapent Ethyl | Icosapent Ethyl | 53 | 17 |
| Repatha Syringe | Evolocumab | 51 | suppressed |
| Linzess | Linaclotide | 50 | suppressed |
| Januvia | Sitagliptin Phosphate | 48 | 14 |
| Prednisone | Prednisone | 47 | 27 |
| Dexlansoprazole Dr | Dexlansoprazole | 45 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 44 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 42 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 41 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 41 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 15 |
| Warfarin Sodium | Warfarin Sodium | 41 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 40 | suppressed |
| Tradjenta | Linagliptin | 40 | suppressed |
| Bupropion Xl | Bupropion Hcl | 39 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 39 | 13 |
| Celecoxib | Celecoxib | 38 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 37 | suppressed |
| Olanzapine | Olanzapine | 37 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 36 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 36 | suppressed |
| Fluconazole | Fluconazole | 35 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Spironolactone | Spironolactone | 35 | 12 |
| Indapamide | Indapamide | 33 | 12 |
| Valacyclovir | Valacyclovir Hcl | 33 | 18 |
| Amoxicillin | Amoxicillin | 32 | 24 |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Glipizide | Glipizide | 32 | suppressed |
| Glipizide Er | Glipizide | 32 | suppressed |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Naproxen | Naproxen | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 24 |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Hydrocortisone | Hydrocortisone | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 27 | suppressed |
| Lubiprostone | Lubiprostone | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Ubrelvy | Ubrogepant | 26 | suppressed |
| Ketoconazole | Ketoconazole | 25 | 17 |
| Mometasone Furoate | Mometasone Furoate | 25 | 13 |
| Nystatin | Nystatin | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 20 |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 23 |
| Repaglinide | Repaglinide | 24 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 24 | suppressed |
| Oxycontin | Oxycodone Hcl | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Belsomra | Suvorexant | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 15 |
| Retacrit | Epoetin Alfa-Epbx | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 17 | 17 |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 11 |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 11 |
| Lidocaine | Lidocaine | 15 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 15 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Lacosamide | Lacosamide | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 13 | suppressed |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 13 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 12 | suppressed |
| Praluent Pen | Alirocumab | 12 | suppressed |
| Ramelteon | Ramelteon | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $17,724.10 · 221 records | Amgen Inc. | ACCRUFER, AIRSUPRA, BREZTRI, CAMZYOS, CREON, Cologuard Collection Kit, ELIQUIS, ENTRESTO, EVENITY, FARXIGA, FASENRA, INGREZZA, JARDIANCE, JASCAYD, Kerendia, LEQVIO, LINZESS, MOUNJARO, NURTEC ODT, NUZYRA, OFEV, OTEZLA, Ozempic, PYRUKYND, QULIPTA, RELISTOR, REPATHA, Rybelsus, SYNTHROID, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, XTAMPZA, ZAVZPRET, ZEPBOUND, ZORYVE | 20 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error